Helperby Therapeutics Limited
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 22, 2027The maintenance fee for Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent (US 9,216,186) comes due Jun 22, 2027. Unpaid by Dec 22, 2027, it lapses early.
- 1 fee due Oct 9, 2027The maintenance fee for Combination comprising zidovudine and an antimicrobial compound (US 11,951,119) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,493,071 | Use of Pyrroloquinoline Compounds to Kill Clinically Latent Microorganisms In force · High confidence | In force | High confidence | |
| US 8,207,187 | Use of Pyrroloquinoline Compounds to Kill Clinically Latent Microorganisms In force · High confidence | In force | High confidence | |
| US 8,940,723 | Combination of a Pyrroloquinoline Compound and a Beta-Lactam Antimicrobial Agent, Mupirocin or Chlorhexidine In force · High confidence | In force | High confidence | |
| US 9,216,186 | Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent In force · USPTO record | In force | USPTO record | |
| US 9,757,427 | Combination comprising zidovudine and polymyxin In force · USPTO record | In force | USPTO record | |
| US 10,736,888 | Triple combination In force · USPTO record | In force | USPTO record | |
| US 10,888,575 | Combination comprising zidovudine and a carbapenem In force · USPTO record | In force | USPTO record | |
| US 11,951,119 | Combination comprising zidovudine and an antimicrobial compound In force · USPTO record | In force | USPTO record | |
| US 12,594,319 | Pharmaceutical Development In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 2 patents in force now held by others · 7 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 10 no status recorded